ravulizumab
ravulizumab: 14 clinical trials tracked.
ravulizumab evidence translation
What we can confirm
14 tracked trials
What it means
What to watch
Prepared research question
What is verified about ravulizumab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence5 indications · 3 study sponsors
Related indications
Clinical Trials (14)showing 10 most recent
A Phase 3b, Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adult Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)
Primary endpoint: Adjudicated On-Trial Annualized Relapse Rate (ARR)
A Non-interventional Study Evaluating Ravulizumab Treatment Outcomes in Polish Patients With Atypical Hemolytic Uremic Syndrome
Primary endpoint: Proportion of patient attaining Complete Thrombotic Microangiopathy (TMA) Response during observation (naïve)
A Comparative Clinical Effectiveness Trial of Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab and Eculizumab To Prevent Relapses in Neuromyelitis Optica Spectrum Disorder
Primary endpoint: Time to adjudicated safety or tolerability failure
OCTAGON: A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients With Generalized Myasthenia Gravis Treated With Ravulizumab
Primary endpoint: Proportion of Adult Participants With gMG Who Either: Discontinue Oral Corticosteroids (OCS) or Reduce Their Daily OCS Dosage ≤ 5 mg/day and Maintain this Status for ≥ 4 Weeks Without Clinical Deterioration of gMG
Multicenter, Open-label, Single-arm, Post-Marketing Clinical Study to Evaluate the Efficacy and Safety of Ravulizumab in Participants Clinically Diagnosed as Atypical Hemolytic Uremic Syndrome
Primary endpoint: Percentage of Participants Showing Improvement in Platelet Count During the 26-week Ravulizumab Treatment
A Phase 3, Open-Label, Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to < 18 Years of Age) With Primary Immunoglobulin A Nephropathy (IgAN)
Primary endpoint: Change from Baseline in Proteinuria Based on Urine Protein to Creatinine Ratio (UPCR) at Week 34
A Phase 3, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab Administered Intravenously in Adult Participants at High Risk of Delayed Graft Function After Kidney Transplantation
Primary endpoint: Time to Freedom from Dialysis
Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).
Primary endpoint: Change from baseline in Myasthenia Gravis-Activities of Daily Living (MG-ADL) total score
Real-life Treatment Outcomes of Ravulizumab in Polish Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH). Prospective and Retrospective, Multicenter, Non-interventional Study.
Primary endpoint: Change in LDH levels from index date (first dose of ravulizumab) at every 6 month
A Phase 3, Single-arm, Open-label, Multicenter Study to Assess the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Complement Inhibitor Treatment Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in China
Primary endpoint: Percentage Change in Lactate Dehydrogenase (LDH) From Baseline to Day 183 (Week 26)